Basic COX-2 inhibitor agreement sets stage for RaQualia's first Chinese deal
This article was originally published in Scrip
Executive Summary
Japan's RaQualia Pharma has signed a basic agreement with two partners in China for the licensing and co-development in this market of cyclooxygenase-2 inhibiting molecules.